Once-Weekly Semaglutide 7.2 mg Beats Placebo for Obesity
Second study shows 7.2 mg semaglutide leads to greater reductions in mean body weight for those with obesity, T2D
Evidence Insufficient to Determine Benefits of Multicancer Screening Tests
Sensitivity ranged from 0.095 to 0.998; specificity from 0.657 to 1.0; AUC from 0.52 to 1.0 across tests
High Exposure to Prenatal Prescribed Opioid Analgesics Likely Not Associated With ASD Risk
Associations were largely or fully attenuated using designs other than accounting for measured confounders and in sibling comparisons
Influenza-Linked Hospitalization Rate High in 2024 to 2025 Flu Season
Cumulative influenza-associated hospitalization rate surpassed end-of-season rates during period starting with 2010 to 2011 season
GLP-1 RAs Cost-Effective Versus Usual Care for Knee OA, Obesity
Tirzepatide offers more favorable return on investment, but greater benefits seen at lower costs for Roux-en-Y gastric bypass
Over-the-Counter Naloxone Shows Limited Uptake
Sales are a fraction of pharmacy-dispensed and program-distributed naloxone
FDA Cracks Down on Hims, Other Telehealth Companies Over Drug Ads
Hims was flagged for misleading claims about compounded Ozempic/Wegovy
Half Discontinue Semaglutide for Weight Loss Within One Year
Factors tied to discontinuation included younger age, male sex, socioeconomic deprivation, higher comorbidity level
U.S. Officials to Review COVID Vaccine Safety in Pregnancy, Kids
So far, large federal studies have shown no higher risk for major birth defects, miscarriage or other complications
RFK Jr. Adds 5 Members to Vaccine Advisory Committee Ahead of Meeting
Three of the appointees have previously questioned aspects of COVID-19 response and vaccines
